Olga Martínez-Sáez

11PUBLICATIONS
118CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCellular nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 10, 2026
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Jul 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Mar 30, 2023
Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer.

Olga Martínez-Sáez, Adrienne G Waks

|Mar 01, 2023
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.

Aleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez

Pageof 2

Frequent Collaborators

4 joint publications

Fara Brasó-Maristany

3 joint publications

Aleix Prat

3 joint publications

Tomás Pascual

3 joint publications

Cristina Saura